- Novo Nordisk’s CFO focuses on the U.S. launch of Wegovy and advancing its pipeline. Shares rose 2.7% to 314.10 kroner, with a target price of 400 kroner.1
- Healthify’s CEO announced plans to expand its Novo-linked support program for GLP-1 receptor agonists globally, highlighting the significant contribution of their weight-loss initiative to revenue.2







